These data indicate that the AHR-active pharmaceuticals are selective AHR modulators and applications of these drugs for targeting the AHR must be confirmed by studies using the most relevant cell context.
INTRODUCTION
The aryl hydrocarbon receptor (AHR) binds with high affinity to the environmental toxicant 2, 3, 7, and with moderate to low affinity to structurally-diverse health promoting phytochemicals, endogenous biochemicals, and several pharmaceuticals that are clinically used for treating multiple disorders (Denison et al., 2011; Poland et al., 1976; Safe, 1986; Safe et al., 2012) . The molecular mechanism of action of AHR ligands has been extensively investigated, and liganddependent activation of the AHR generally results in formation of a nuclear AHR-AHR nuclear translocator (ARNT) heterodimer which binds dioxin responsive elements (DREs) in target gene promoters to activate transcription (Denison et al., 2011) .
Studies in this laboratory initially focused on development of AHR antagonists that inhibited TCDD-induced toxicity and we identified 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) as an inhibitor of TCDD-induced CYP1A1, porphyria, immunotoxicity and teratogenicity in rodent models (Astroff et al., 1988; Bannister et al., 1989; Harris et al., 1989; Yao and Safe, 1989) .
However, MCDF did not inhibit TCDD-induced antiestrogenic effects in the rodent uterus or human breast cancer cells but acted as an AHR agonist (Astroff and Safe, 1991; Zacharewski et al., 1992) , and subsequent studies showed that MCDF also inhibited ER-positive and ER-negative breast cancer cell and tumor growth (McDougal et al., 2001; Zhang et al., 2012; Zhang et al., 2009 ).
Thus, MCDF was one of the first compounds characterized as a selective AHR modulator (SAhRM) that exhibits tissue-selective AHR agonist or antagonist activities (Astroff and Safe, 1991; McDougal et al., 2001; Zacharewski et al., 1992; Zhang et al., 2012; Zhang et al., 2009) , and several other AHR antagonists and SAhRMs have been 5
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identified (Boitano et al., 2010; Murray et al., 2011; Murray et al., 2010; Smith et al., 2011; Zhao et al., 2010) .
In this study, we investigated the activity of eight AHR-active pharmaceutical agents as SAhRMs in two different Ah-responsive breast cancer cell lines; namely ERnegative MDA-MB-468 cells and epidermal growth factor receptor 2 (ErbB2)-overexpressing BT474 cells (Zhang et al., 2009 ). Both cell lines are aggressive and represent sub-classes of breast cancer that do not respond well to endocrine therapy but are growth inhibited by TCDD and MCDF (Zhang et al., 2009) . The pharmaceuticals (and their applications) include leflunomide (antiinflammatory), flutamide (antiandrogen), nimodipine (calcium channel blocker), mexiletine (antiarrhythmic) and sulindac (antiinflammatory) which induce CYP1A1 rodent systems (in vivo and in vitro) (Ciolino et al., 2006; Hu et al., 2007; O'Donnell et al., 2010) ; tranilast (antiallergic drug) which exhibits AHR agonist activity and inhibits breast cancer cell and stem cell growth (Prud'homme et al., 2010) ; 4-hydroxytamoxifen which induces CYP1A1/1B1 in breast cancer cells and suppresses osteoclast differentiation (DuSell et al., 2010) ; and omeprazole (Dzeletovic et al., 1997; Hu et al., 2007; Quattrochi and Tukey, 1993) which also induces CYP1A1 and exhibits other AHR agonist activities.
We investigated the effects of these pharmaceuticals on AHR expression, CYP1A1
(protein and mRNA), CYP1B1 mRNA, and functional responses in MDA-MB-468 and BT474 cells, and compared these effects to results for TCDD. The Ah-responsiveness of these agents was highly variable and dependent on the response and cell context. Cells were maintained at 37C in the presence of 5% CO 2 , and the solvent (DMSO) used in the experiments was ≤0.2%. CYP1A1, CYP1B1, AHR, and -actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All compounds used in this study were purchased from Sigma-Aldrich (St. Louis, MO). The reagents for MTT assay and cell staining were supplied by Sigma-Aldrich.
Cell proliferation (MTT) and ethoxyresorufin-O-deethylase (EROD) assays.
Cells (5 x 10   3 per well) were plated in 96-well plates and allowed to attach for 16 hr.
The medium was then changed to DMEM medium containing 2.5% FBS, and either vehicle (DMSO) or different concentrations of the compounds were added. After 24 hr, treatment medium was replaced with fresh medium containing 0.05 mg of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) per 100 μL and incubated for 4 hr. Medium was then removed, and 100 μL of dimethyl sulfoxide was added to wells.
The optical density of each sample was read on a microplate reader (FLUOstar OPTIMA) at 570 nm against a blank prepared from cell-free wells. Cell proliferation was expressed as a % of relative absorbance of untreated controls. EROD assays were determined as described {Zhang, 2009 #12}. TCDD, leflunomide, nimodipine, mexiletine, omeprazole and tranilast also induced CYP1B1 protein in MDA-MB-468 cells, whereas minimal to non-detectable levels were observed after treatment with 4-hydroxytamoxifen, sulindac or flutamide (Suppl. Fig. 4 ).
In contrast, only TCDD, leflunomide and nimodipine induced CYP1B1 protein in BT474
cells. There was minimal correlation between induction of CYP1A1 protein ( Fig. 1 ) and CYP1A1 mRNA levels for most of the AHR-active pharmaceuticals ( Figs. 2A-2D ). In MDA-MB-468 cells, only omeprazole induced CYP1A1 mRNA levels that were >30% of that observed for TCDD (Fig. 2C ), whereas concentrations of leflunomide (50 and 100 M) induced CYP1A1 protein levels similar to that observed for TCDD ( is a potent inducer of CYP1A1 (Wang et al., 1997) . BT474 is a highly aggressive cancer cell line that overexpresses the ErbB2 oncogene, and TCDD inhibits cell growth, migration/invasion but exhibits minimal induction of CYP1A1 (>10-fold).
Initially, we investigated the growth inhibitory effects of these compounds since this response might impact Ah-responsiveness and would affect interpretation of functional cell migration studies. Differences in growth inhibition were compound-and cell context-dependent. Growth inhibition was observed for all compounds except tranilast at the highest concentration used and, among the remaining pharmaceuticals, sulindac preferentially inhibited growth of MDA-MB-468 vs. BT474 cells (Suppl. Fig. 1 ).
The results for tranilast were somewhat surprising since previous studies showed that a 200 µM concentration inhibited BT474 cell growth and migration (Quintana et al., 2010; Subramaniam et al., 2011; Subramaniam et al., 2010) . We also observed Ah- (Fig. 4) . In contrast, a ChIP assay indicated that all three compounds recruited the AHR complex to the CYP1A1 promoter in MDA-MB-468 cells, even though CYP1A1 induction was not observed (Fig. 5) .
Thus, for a series of eight pharmaceuticals previously identified as AHR agonists in different assays and cell lines (Ciolino et al., 2006; DuSell et al., 2010; Dzeletovic et al., 1997; Hu et al., 2007; O'Donnell et al., 2010; Prud'homme et al., 2010; Quattrochi and Tukey, 1993; Subramaniam et al., 2011; Subramaniam et al., 2010) , the AHR agonist and antagonist activities were structure-, cell context-, and response-dependent (Table 1) . Mexiletine is an excellent example of these differences; this compound exhibited AHR agonist activity in rodent liver and rodent hepatoma cell lines (Hu et al., 2007) and was an AHR antagonist in MDA-MB-468 cells (Fig. 4) . The effects of the AHR-active pharmaceuticals on MDA-MB-468 cell migration were also structuredependent; however, it is possible that this response was a combination of AHRdependent and -independent pathways, and this is currently being investigated.
Omeprazole was the most consistent AHR agonist and the most potent inhibitor of cell migration (Fig. 6 ) which was AHR-dependent (Suppl. Fig. 5 ), and our current studies are focused on development of this agent and structurally-related compounds for treating ER-negative breast cancer.
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